Grifols preps blood clot treatment approval push after ph. 3 win
EMA Withdraws Marketing Authorisation of Mallinckrodt Pharmaceuticals' Raplixa (human fibrinogen)
EMA Statement on Withdrawing Marketing Authorisation of Mallinckrodt's Raplixa (human fibrinogen)
EMA Assessment & Procedural Steps taken for marketing authorisation withdrawal of Mallinckrodt's Raplixa (human fibrinogen)
Instituto Grifols, S.A. VeraSeal (human fibrinogen / human thrombin) Receives Approval In Europe